China's rapid development in the medical field in recent years is obvious to all, and the technology in oncology medicine has also been relatively mature. The establishment of Precise prevention, diagnosis and treatment plan and clinical decision-making system of tumor risk assessment, prediction and early warning, early screening, classification and classification, individualized treatment, efficacy and safety prediction and monitoring have become important research contents of precision medicine.

Before the 6th WPMCS-2021 Genetic Testing and In Vitro Diagnosis Conference held at Guangzhou Sunac Wanda Realm Hotel on June 4-5, we were honored to interview Li Jie, the founder of Putian (Tianjin) Biotechnology Co., Ltd. . Invite him to share with us what he thinks is the current status and future of the clinical application of tumor precision medicine.

Doctor of Medicine, Distinguished Professor of General Hospital of Tianjin Medical University, Founder of Putian (Tianjin) Biotechnology Group, and member of Tianjin Thousand Talents Program. Dr. Li Jie received his Ph.D. from Tianjin Medical University Institute of Neurology in 1998. From 1993 to In 2001, he served as attending physician and associate professor in Department of Neurosurgery, General Hospital of Tianjin Medical University. Since 2001, Dr. Li Jie went to work in the United States, and successively completed post-doctorate and fellowship at the National Institutes of Health (NIH), worked as a researcher at Yale University School of Medicine, and Director of the Sample Bank of Yale University Cancer Center. The main research direction is to provide individualized and precise diagnosis and treatment of diseases through comprehensive analysis of multiple omics such as genomics, proteomics, and metabolomics. Returned to China in 2014 and applied multi-omics analysis to medical transformation.

Question: Professor Li, you have been working in the U.S. since 2001, so what thought led you to found Pu Tian?

Professor Li: In 2014, I resigned from Yale University and returned to China to start a full-time business, and set up PuTian Bio. Someone asked me, "Why did you switch to starting a business? Isn't it good to conduct medical research in the United States?" In fact, I didn't "change my career", but because of my many years of accumulation, I found a medical environment that is more conducive to exerting my strengths. Since I was a surgeon, I have had a dream, that is, a scalpel may be able to save a hundred or ten thousand patients. However, a breakthrough in medical technology may protect the entire human race from some diseases. Diagnosis and treatment based on protein molecular analysis is such a technical field that contains unlimited medical prospects, especially when I see a large number of gene sequencing platform results that have not been verified at the protein level, and protein profiling technology has become qualitative in recent years. At the time of Feiyue, I hope that through my unremitting efforts, I will develop and apply this technology to clinics and serve the "individualized precision medicine" advocated worldwide. If my dream can be realized one day in the future, then we will be able to provide patients with more accurate and efficient individualized diagnosis, until we provide a "private customized" treatment plan. For me, the "entrepreneurship" I am engaged in is a passionate technical challenge, but also a medical revolution of extraordinary significance.

Question: PuTian Biology adheres to the "Trinity" multi-omics precision medicine concept. Can you analyze the "Trinity" model in detail? What work has our company done to implement this concept? 

Professor Li: In fact, the so-called "Trinity" is a multi-omics analysis platform based on genes, proteins, and metabolism. It collects, integrates and analyzes the three omics information of solid tumor patients' genome, proteome and metabolome, and comprehensively extracts the individual patients. It provides clinical and scientific research test results for clinicians involved in precision medicine practice. While meeting the doctor’s scientific research needs, it pushes the precision of clinical diagnosis and treatment plans such as targeted drugs, immunotherapy and nutritional therapy to the extreme, and ultimately expands precision treatment The scope of the beneficiary population, the increase of the types of drugs to choose from, and the correction of the results of genetic testing at the same time enable the individualized characteristics of patients to be more comprehensive and accurate, and to achieve the purpose of precision medicine.

Since its establishment, PUTIAN has always used the standards of listed companies to demand itself. We regard technological innovation as an inexhaustible driving force for corporate growth. In the medical field, Specian vigorously promotes individualized disease analysis and treatment with multi-omics as the core, and creates a new brand of "Putian Health" with independent intellectual property rights through continuous development of protein-centric medical diagnosis and treatment products.

Question: What are the biggest advantages of the "Trinity" applied to tumor precision medicine compared with the traditional ones?

Professor Li: Different from common tumor detection products on the market, Putian incorporates environmental pathogenic factors other than genes (genetic pathogenic factors) into the analysis of diseases. As we all know, the transmission of genetic information revolves around the central principle. The genome is the carrier of genetic information. Genes are transcribed to form mRNA, and translated to form proteins. Eventually function at the protein level, and produce effects or leave traces at the metabolic level. As a result, PUTIAN has established a multi-omics analysis platform based on the “trinity” of gene, protein, and metabolism, and based on high-throughput sequencing NGS, high-throughput sequencing. A clinically established analysis platform that distinguishes mass spectrometry LC/MS/MS and nuclear magnetic resonance spectroscopy NMR, collects, integrates and analyzes the three aspects of solid tumor patient genome, proteome and metabolome information. For the proteome platform, the company strives to shorten the detection At the same time of the analysis cycle, the demand for sample volume is further reduced, and the processing of complex samples is optimized, so that the acquired data can be more accurate and faster to meet the needs of personalized diagnosis.

At the same time, for the self-developed patented UmbrellaTM computer platform, we have a database of 60,000 clinical samples and an exclusive innovative network analysis method. For lung cancer, bowel cancer, brain tumors and other tumors, there are separate cancer database and reporting systems. To achieve automation, we are constantly expanding the database and optimizing algorithms to bring more accurate results to patients. For the metabolome platform, using the most advanced nuclear magnetic equipment in China to further accumulate the amount of data, a database of different metabolic-related diseases will be established for different patient populations to provide accurate indicators for the diagnosis of different diseases. While expanding the beneficiary population, expand the scope of medication, so that more cancer patients have medicine to take, and the medicine is effective.

Question: Your topic for this summit is the clinical application of tumor precision medicine based on multi-omics analysis. In what aspects will it be elaborated? Can you send a message to the conference? Looking forward to your wonderful speech!

Professor Li: Firstly, discuss the current status and bottlenecks of precision medicine, where are the difficulties and pain points, and secondly, what are the current solutions to this problem, and what new technologies and methods can supplement this difficulty and promote more accurate tumor diagnosis and treatment , A comprehensive analysis from the three omics, jumps to the appearance, you can see the future development direction of tumor precision medicine. I hope all colleagues can talk freely in the ocean of precision medicine, and hope that the conference will be a complete success!

Speech preview

Thank you Professor Li for accepting the interview of the Organizing Committee of the 2021 6th Genetic Testing and In Vitro Diagnosis Conference. Professor Li will be at the General Assembly on June 4: Exploration of the In Vitro Diagnosis Industry in the New Era, bringing you "Tumor based on multi-omics analysis" Please look forward to the wonderful report on Clinical Application of Precision Medicine!

报名参会

Participation fee: 2180 yuan/person

On-site payment: 2800 yuan/person

Group purchase price: 15% off for 3 people and more

   *In order to strengthen on-site academic exchanges and be grateful to the anti-epidemic angels, doctors of medical institutions, staff of national scientific research units, and college-related professional students can obtain exclusive welfare prices with work permits and student cards. For details, please contact Ms. Wang from the conference affairs team at 17701745462 ( WeChat same)